Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterization and Modulation of Brain Networks to Promote Brain Resilience for the Coronavirus (COVID-19) Pandemic

NCT05293431 is registered in ClinicalTrials.gov with Institut Guttmann as lead sponsor.

NCT NCT05293431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05293431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterization and Modulation of Brain Networks to Promote Brain Resilience for the Coronavirus (COVID-19) Pandemic
Lead sponsor
Institut Guttmann
Phase
Not applicable
Overall status
Unknown status
Start date
September 1, 2022
Completion date
November 15, 2023
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, mental health issue, public health, resilience, psychological, transcranial direct current stimulation